Woodline Partners’s Century Therapeutics IPSC Stock Holding History

Woodline Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Buy	4,257,530 +1,214,052	+40%	+$2.77M	0.03%	523
2026 Q1	$6.88M	Buy	+3,043,478	New	+$6.4M	0.03%	598
2022 Q3	–	Sell	-208,082	Closed	-$1.75M	–	787
2022 Q2	$1.75M	Hold	208,082	–	–	0.03%	451
2022 Q1	$2.62M	Hold	208,082	–	–	0.04%	342
2021 Q4	$3.3M	Sell	208,082 -42,012	-17%	-$789K	0.05%	343
2021 Q3	$6.29M	Sell	250,094 -31,632	-11%	-$856K	0.1%	225
2021 Q2	$8.27M	Buy	+281,726	New	+$7.15M	0.15%	154

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners's IPSC Position: Q2 2026 in Review

Woodline Partners increased its Century Therapeutics (IPSC) stake by 40% in Q2 2026, buying an estimated $2.77M and bringing the position to 4,257,530 shares worth $10.4M. The position accounts for 0.03% of the portfolio, ranked #523.

Woodline Partners first reported a position in IPSC in Q2 2021 and has held it in 7 quarters since. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Woodline Partners held 4,257,530 shares of Century Therapeutics worth $10.4M as of Q2 2026.
Woodline Partners bought 1,214,052 Century Therapeutics shares in Q2 2026, an estimated $2.77M.
Century Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #523 holding.
Woodline Partners first reported a position in Century Therapeutics in Q2 2021 and has held it in 7 quarters since.
99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.